Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $145.11, while State Street SPDR S&P Biotech ETF trades at $159.44. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| SOXL | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $300.77 | $164.28 |
52-Week Low | $24.91 | $88.79 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 9.35% to $142.16 amid renewed semiconductor sector optimism. The ETF remains in a technical bearish trend despite the daily rally, with moving averages signaling caution. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the leveraged structure amplifies volatility risks. Financial ratios are unavailable as this is a leveraged ETF tracking semiconductor stocks rather than a traditional company.
SOXL offers aggressive exposure to semiconductor sector rebounds but carries elevated risk due to 3x daily leverage. The current technical setup suggests caution despite positive sentiment around AI chip demand. Key risks include sector volatility, leverage decay, and geopolitical tensions affecting semiconductor supply chains. Investors should understand the specialized nature of leveraged ETFs before considering positions.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
